Pfizer Aktie News

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Trump, according to sources familiar with the situation.

Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.

Lower demand for COVID-19 treatments has been hurting Pfizer's revenue. Pfizer also has major products losing patent protection over the next couple of years.

PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free...

Expand NYSE: PFE Pfizer Today's Change (-3.40%) $-0.90 Current Price $25.53 Key Data Points Market Cap $150B Day's Range $24.92 - $26.50 52wk Range $20.91 - $27.69 Volume 112M Avg Vol 68M Gross Margin 69.12% Dividend Yield 6.51% Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 ...

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.

Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion.